Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Quality of life scores demonstrate prognostic value in ovarian cancer

06 Jul 2017

Quality of life (QoL) scores, particularly in the domains of physical function and abdominal/gastrointestinal symptom, provide additional prognostic information to survival prediction in platinum-resistant ovarian cancer, according to a study.

Researchers used data from the AURELIA study involving 326 patients randomized to receive chemotherapy with or without bevacizumab to identify baseline QoL domains (EORTC QLQ-C30 and OV28) significantly associated with overall survival. Risk categories for physical function and abdominal/gastrointestinal symptom were defined as good, medium or low.

Univariable analysis showed that all domains, with the exception of cognitive function, predicted overall survival, but only physical function and abdominal/gastrointestinal symptom scores remained significantly associated with survival in multivariable models (p<0.001 for both).

In patients with high (score <67), medium (67 to 93) and low (>93) risk categories for physical function, the respective median overall survival was 11.0, 14.7 and 19.3 months (p<0.001). In an independent cohort (CARTAXHY; n=136), the corresponding median overall survival was 7.9, 16.2 and 23.9 months (p<0.001).

In patients with high (>44), medium (13 to 44) and low (<13) risk categories for abdominal/gastrointestinal symptoms, the respective median overall survival was 11.9, 14.3 and 19.7 months in the AURELIA cohort (p<0.001) and 10.5, 19.6 and 24.1 months in CARTAXHY (p=0.02).

Physical function (p=0.02) and abdominal/gastrointestinal symptoms (p=0.03) remained independent prognostic factors for overall survival after controlling for clinicopathologic factors. The C-statistic of the full model was 0.71. Separately, the respective C-statistics for quality of life factors, patient factors and disease factors were 0.61, 0.61 and 0.67.

The present data indicate that physical function and abdominal/gastrointestinal symptom scores can improve predictions of overall survival in platinum-resistant ovarian cancer when compared with clinicopathologic factors alone.

Researchers said the additional prognostic information could improve trial stratification, patient-doctor communication about prognosis and clinical decision making.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.